Patents Examined by Jason Sims
-
Patent number: 9708301Abstract: The present invention relates to the novel solid forms of Afatinib monomaleate and preparation methods thereof; the solid forms of Afatinib monomaleate of the present invention have many improved properties as compared to the known crystalline form of Afatinib salt; and the present invention also relates to pharmaceutical compositions containing the novel solid forms of Afatinib monomaleate as well as the uses thereof for treating terminal non-small cell lung cancer (NSCLS) and HER2 positive advanced breast cancer.Type: GrantFiled: January 14, 2016Date of Patent: July 18, 2017Assignee: HANGZHOU PUSHAI PHARMACEUTICAL TECHNOLOGYInventors: Xiaohong Sheng, Jianfeng Zheng, Xiaoxia Sheng
-
Patent number: 9701947Abstract: The invention relates generally to methods and compositions concerning desaturase enzymes that modulate the number and location of double bonds in long chain poly-unsaturated fatty acids (LC-PUFA's). In particular, the invention relates to methods and compositions for improving omega-3 fatty acid profiles in plant products and parts using desaturase enzymes and nucleic acids encoding for such enzymes. In particular embodiments, the desaturase enzymes are Primula ?6-desaturases. Also provided are improved soybean oil compositions having SDA and a beneficial overall content of omega-3 fatty acids relative to omega-6 fatty acids.Type: GrantFiled: July 17, 2012Date of Patent: July 11, 2017Assignee: Monsanto Technology LLCInventors: Virginia Ursin, Byron Froman, Jennifer Simmons, Thomas J. LaRosa, Fenggao Dong, Steven Screen
-
Patent number: 9681836Abstract: Methods, systems, and apparatuses for detecting seizure events are disclosed, having at least one accelerometer to be positioned on a patient and configured to collect acceleration data and a processor in communication with the at least one accelerometer and configured to receive acceleration data from the at least one accelerometer. The processor may apply at least one non-linear operator to the acceleration data to determine whether the acceleration data indicates an event, such application including calculation of a non-linear energy of the acceleration data and performance of at least one secondary analysis to determine whether the event is a seizure.Type: GrantFiled: July 25, 2012Date of Patent: June 20, 2017Assignee: CYBERONICS, INC.Inventor: Shivkumar Sabesan
-
Patent number: 9679103Abstract: Haplotypes of one or more portions of a chromosome of an organism from sequencing information of DNA or RNA fragments can be determined. Heterozygous loci (hets) can be used to determine haplotypes. One allele on a first het can be connected (likely to be on the same haplotype) to an allele on a second het, thereby defining a particular orientation between the hets. Haplotypes can be assembled through these connections. Errors can be identified through redundant connection information, particularly using a confidence value (strength) for a particular connection. The connections among a set of hets can be analyzed to determine likely haplotypes for that set, e.g., an optimal tree of a graph containing the hets. Furthermore, haplotypes of different contiguous sections (contig) of the chromosome can be matched to a particular chromosome copy (e.g., to a particular parental copy). Thus, the phase of an entire chromosome can be determined.Type: GrantFiled: August 22, 2012Date of Patent: June 13, 2017Assignee: Complete Genomics, Inc.Inventors: Bahram Ghaffarzadeh Kermani, Radoje Drmanac
-
Patent number: 9672271Abstract: A reorganization of genomic data into a simpler standard form leads to more transparent data analyses. The customary selection practice that focuses on high odds ratios loci is shown to be biased, reflecting quality of presently reported risk loci for T2D. A selection criterion, based on Shannon information theory, brings clarity to this issue and provides a rational and optimal basis for selecting potential risk loci. This is used to determine an optimal disease classifier. Within the framework of the FUSION database this leads to a relatively successful degree of T2D prediction and nearly an order of magnitude more effective in detecting T2D. Chromosome 7 is strongly associated with T2D. A hypothesis of this study is that the genomic disease signal is possibly weak, and instead of focusing on individual loci a collection of loci contribute to a composite Score, which functions as the determinant of disease or its absence.Type: GrantFiled: May 2, 2014Date of Patent: June 6, 2017Inventor: Lawrence Sirovich
-
Patent number: 9670363Abstract: The invention discloses new substituted anthraquinone dyes that may be useful as cellular stains. In some aspect of the invention, the nuclear stains are useful for staining the nuclei of dead or fixed cells. Another aspect of the invention relates to substituted anthraquinone dyes comprising an enzyme substrate moiety that is transformable or cleavable by an enzyme such that the transformation or cleavage of the substrate moiety causes a detectable change in the functionality or spectral properties of the dye.Type: GrantFiled: April 9, 2014Date of Patent: June 6, 2017Assignee: Biotium, Inc.Inventors: Fei Mao, Wai-Yee Leung, Ching-Ying Cheung, Lori Michelle Roberts
-
Patent number: 9670179Abstract: Embodiments of the present disclosure provide for compositions including an antibiotic containing a N-thiolated beta-lactam moiety, pharmaceutical compositions including the antibiotic, methods of treatment of a condition (e.g., bacterial infection), methods of treatment using compositions or pharmaceutical compositions, and the like.Type: GrantFiled: March 13, 2014Date of Patent: June 6, 2017Assignee: University of South FloridaInventors: Edward Turos, Biplob Bhattacharya
-
Patent number: 9670530Abstract: Methods of determining a haplotype or partial haplotype of a DNA sample containing high molecular weight segments of genomic DNA are disclosed. Such methods may include sequencing DNA in an enriched DNA sample to produce a plurality of sequence reads, where some of the sequence reads contain a first allele of the first haplotype and other of the sequence reads contain a second allele of the first haplotype. Some methods align the sequence reads to a reference genome to produce aligned reads, where aligned reads from the first high molecular weight segment tend to cluster into islands on the reference genome. Some methods further determine distances separating adjacent aligned reads on the reference genome and select a first group of the aligned reads having separation distances to adjacent aligned reads that are smaller than a cutoff value. Using alleles from the first group of aligned reads, the method may define a first haplotype or first partial haplotype.Type: GrantFiled: January 30, 2014Date of Patent: June 6, 2017Assignee: Illumina, Inc.Inventors: Emrah Kostem, Sasan Amini
-
Patent number: 9662309Abstract: The present invention relates to the use of macrocyclic lactones for treating demodicosis, particularly in dogs.Type: GrantFiled: October 27, 2005Date of Patent: May 30, 2017Assignee: BAYER INTELLECTUAL PROPERTY GMBHInventors: Josef Heine, Klemens Krieger
-
Patent number: 9656015Abstract: A body fluid purifying arrangement comprises a purifying chamber having a fluid input and a fluid output, a first filter arranged in connection the fluid input, and a second filter arranged in connection with the fluid output. In another embodiment, a body fluid purifying arrangement in the form of a syringe comprises a purifying chamber having a common fluid input and fluid output, and a filter arranged in connection with the common fluid input and output. Granules or particles made of a metal or an oxide of a metal are retained within the purifying chamber by the respective filter(s) to purify a body fluid passing through the purifying chamber from 10 kDa interferon-? inducible protein, IP-10, wherein said metal is a metal of group 4 or 5 of the periodic table of the elements and selected from the group consisting of titanium, zirconium, hafnium, niobium and tantalum.Type: GrantFiled: June 23, 2014Date of Patent: May 23, 2017Assignee: PROPHY MED ABInventors: Lars Bruce, Staale Petter Lyngstadaas
-
Patent number: 9657033Abstract: The invention provides tetrahydronaphthyridine and related compounds, pharmaceutical compositions, methods of inhibiting ROR? activity, reducing the amount of IL-17 in a subject, and treating immune disorders and inflammatory disorders using such tetrahydronaphthyridine and related compounds.Type: GrantFiled: May 7, 2013Date of Patent: May 23, 2017Assignees: Lycera Corporation, Merck Sharp & Dohme Corp.Inventors: Thomas D. Aicher, Kenneth J. Barr, Blair T. Lapointe, Vladimir Simov, Karin A. Stein, William D. Thomas, Peter L. Toogood, Chad A. Van Huis, Catherine M. White
-
Patent number: 9649426Abstract: A method of treating or preventing a disease characterized by adverse expression and/or release of 10 kDa interferon-? inducible protein, IP-10, comprises administering granules or particles made of a metal or an oxide of a metal to a subject suffering from the disease. A method of reducing IP-10 in a subject suffering from a disease characterized by adverse expression and/or release of IP-10 comprises administering granules or particles made of a metal or an oxide of a metal to the subject. The metal is a metal of group 4 or 5 of the periodic table of the elements and selected from the group consisting of titanium, zirconium, hafnium, niobium and tantalum.Type: GrantFiled: June 23, 2014Date of Patent: May 16, 2017Assignee: PROPHY MED ABInventors: Lars Bruce, Staale Petter Lyngstadaas
-
Patent number: 9649275Abstract: The present invention relates to oil-in-water nanoemulsions, processes for their preparation and their use as delivery vehicles for active components for use in opthalmological, dermatological, food, cosmetic, pharmaceutical, agrichemical, textile, polymer and chemical applications. The oil-in-water nanoemulsion comprises up to 40 volume % of an oil phase comprising at least 50 volume % of a triglyceride having a fatty acid chain length of 12 carbon atoms or greater and a hydrophilic non-ionic surfactant having a hydrophilic-lipophilic balance (HLB) greater than 7; and an aqueous phase, in which the oil droplets have an intensity average size of less than 100 nm and the ratio of surfactant to oil is less than 1:1, more preferably 0.2 to 0.8:1.Type: GrantFiled: November 18, 2008Date of Patent: May 16, 2017Assignee: COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATIONInventors: Timothy James Wooster, Helen French Andrews, Peerasak Sanguansri
-
Patent number: 9650677Abstract: Gene expression profiling in multiple myeloma patients identifies genes that distinguish between patients with subsequent early death or long survival after treatment. Poor survival is linked to over-expression of genes such as ASPM, OPN3 and CKS1B which are located in chromosome 1q. Given the frequent amplification of 1q in many cancers, it is possible that these genes can be used as powerful prognostic markers and therapeutic targets for multiple myeloma and other cancer.Type: GrantFiled: May 21, 2013Date of Patent: May 16, 2017Assignee: BIOVENTURES, LLCInventors: John D. Shaughnessy, Fenghuang Zhan, Bart Barlogie
-
Patent number: 9639657Abstract: Disclosed herein is a system and method for making allele calls, and for determining the ploidy state, in one or a small set of cells, or where a limited quantity of genetic data is available. Poorly or incorrectly measured base pairs, missing alleles and missing regions are reconstructed and the haplotypes are determined using expected similarities between the target genome and the knowledge of the genomes of genetically related individuals. In one embodiment, incomplete genetic data from an embryonic cell are reconstructed at a plurality of loci using the genetic data from both parents, and possibly one or more sperm and/or sibling embryos. In another embodiment, the chromosome copy number can be determined using the same input data. In another embodiment, these determinations are made for embryo selection during IVF, for non-invasive prenatal diagnosis, or for making phenotypic predictions.Type: GrantFiled: March 18, 2013Date of Patent: May 2, 2017Assignee: Natera, Inc.Inventors: Matthew Rabinowitz, George Gemelos, Milena Banjevic, Allison Ryan, Joshua Sweetkind-Singer
-
Patent number: 9629859Abstract: The invention relates to novel NO donors which are targeted to the mitochondria. The NO donor compounds of the invention allow NO to be selectively provided to the mitochondria.Type: GrantFiled: May 19, 2015Date of Patent: April 25, 2017Assignee: Medical Research CouncilInventors: Robin Andrew James Smith, Michael Patrick Murphy
-
Patent number: 9624549Abstract: A method for determining genes in breast cancer that are stable in copy number, expression and sequence in tumors from nearly all patients. Certain stable genes are targets of standard chemotherapy. The effectiveness of therapies that act upon these targets depends on maintaining the stability and integrity of these genes in tumors. Mutations in these targets result in poor response to therapies that target these gene products. In the instant invention, ordinarily stable gene targets are characterized as either normal or mutant for the purpose of determining whether to include or exclude particular drugs as potential treatments.Type: GrantFiled: January 18, 2013Date of Patent: April 18, 2017Assignee: Cytognomix Inc.Inventors: Peter Keith Rogan, Joan Helen Knoll
-
Patent number: 9622996Abstract: A method for treating an cancer disease is disclosed comprising administering to a subject a pharmaceutical composition comprising an adrenergic beta-3-receptor blocker.Type: GrantFiled: January 30, 2013Date of Patent: April 18, 2017Inventors: Shuguang Lin, Meng Zheng
-
Patent number: 9624189Abstract: The invention relates to fluorinated compounds and their use in the field of pathological syndromes of the cardiovascular system. Novel fluorinated benzofuran derivatives of amiodarone and pharmaceutically acceptable salts or solvates thereof and their use for the treatment of arrhythmias are described.Type: GrantFiled: March 12, 2013Date of Patent: April 18, 2017Assignee: SciFluor Life Sciences, Inc.Inventors: Mark E. Duggan, Takeru Furuya, D. Scott Edwards
-
Patent number: 9616010Abstract: The invention relates to a ternary lipid association of ?-sitosterol, isocetyl stearoyl stearate and glyceryl tri-2-ethylhexanoate, wherein the ?-sitosterol content of said association is between 0.1% and 5 wt. %.Type: GrantFiled: July 11, 2014Date of Patent: April 11, 2017Assignees: PIERRE FABRE DERMO-COSMETIQUE, UNIVERSITE PARIS-SUD 11, CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSEInventors: Hélène Duplan, Daniel Redoules, Alexandre Delalleau